Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130047 · ClinicalTrials.gov registry record · Phase 2
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
A Phase 2 study, sponsored by Michael Camilleri, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05130047: Completed Phase 2 study, sponsored by Michael Camilleri, MD.
NCT05130047 is a Phase 2 study that has completed, run by Michael Camilleri, MD. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05130047, a Phase 2 study, has completed, sponsored by Michael Camilleri, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with bile acid malabsorption (BAM).
Interventions
- DRUG Placebo
- DRUG Aldafermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05130047
The ClinicalTrials.gov registry entry for NCT05130047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael Camilleri, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05130047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05130047 about?
NCT05130047 is a clinical study titled "Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)". This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with ...
What is the current status of trial NCT05130047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-12-01. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT05130047?
The interventions under investigation include: Placebo (DRUG), Aldafermin (DRUG).
Who is sponsoring clinical trial NCT05130047?
This trial is sponsored by Michael Camilleri, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.